New TAVR item added to cart for large scale clinical testing Journal Articles

abstract

• Key Points There is no single TAVR prosthesis that can be considered ideal for all patients, needing the development of newer technologies. The GENESIS trial tested 40 patients with the Hydra self‐expandable supra‐annular TAVR with promising results in terms of efficacy, paravalvular leak, and pacemaker risk. Future larger experimental trials are needed to better understand its non‐inferiority to prior technologies.

authors

• Belardi, Jorge A
• Lamelas, Pablo

status

• published 

publication date

• August 2021

has subject area

• 1102 Cardiorespiratory Medicine and Haematology (FoR)
• Aortic Valve (MeSH)
• Aortic Valve Stenosis (MeSH)
• Cardiovascular System & Hematology (Science Metrix)
• Humans (MeSH)
• Transcatheter Aortic Valve Replacement (MeSH)
• Treatment Outcome (MeSH)

published in

• Catheterization and Cardiovascular Interventions  Journal

keywords

• Aortic Valve
• Aortic Valve Stenosis
• Humans
• Transcatheter Aortic Valve Replacement
• Treatment Outcome

Digital Object Identifier (DOI)

• 10.1002/ccd.29855

PubMed ID

• 34369062

start page

• 380

end page

• 381

volume

• 98

issue

• 2